GPRC5A and familial pancreatic carcinoma: These interactions of GPRC5A with HuR, gemcitabine and the other chemotherapeutic agents imply a potential pro-oncogenic role for this gene; therefore, targeting of these interactions could augment the death rate of pancreatic cancer cells post-chemotherapy treatment.